59 related articles for article (PubMed ID: 19960348)
1. Ovarian hyperresponse to luteal phase GnRH-agonist administration.
Depenbusch M; Diedrich K; Griesinger G
Arch Gynecol Obstet; 2010 Jun; 281(6):1071-2. PubMed ID: 19960348
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles.
Tesarik J; Hazout A; Mendoza-Tesarik R; Mendoza N; Mendoza C
Hum Reprod; 2006 Oct; 21(10):2572-9. PubMed ID: 16926261
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
Krause BT; Ohlinger R
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
[TBL] [Abstract][Full Text] [Related]
4. GnRH agonist protocol administration in the luteal phase in ICSI-ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study.
Ata B; Yakin K; Balaban B; Urman B
Hum Reprod; 2008 Mar; 23(3):668-73. PubMed ID: 18192671
[TBL] [Abstract][Full Text] [Related]
5. Beneficial effect of luteal-phase gonadotropin-releasing hormone agonist administration on implantation rate after intracytoplasmic sperm injection.
Razieh DF; Maryam AR; Nasim T
Taiwan J Obstet Gynecol; 2009 Sep; 48(3):245-8. PubMed ID: 19797013
[TBL] [Abstract][Full Text] [Related]
6. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
[TBL] [Abstract][Full Text] [Related]
7. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
Kahraman K; Berker B; Atabekoglu CS; Sonmezer M; Cetinkaya E; Aytac R; Satiroglu H
Fertil Steril; 2009 Jun; 91(6):2437-44. PubMed ID: 18555238
[TBL] [Abstract][Full Text] [Related]
8. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
[TBL] [Abstract][Full Text] [Related]
9. [Onset and maintenance of the luteal phase with GnRH agonists or hCG in cycles under GnRH antagonists].
Olivennes F
J Gynecol Obstet Biol Reprod (Paris); 2004 Oct; 33(6 Pt 2):3S24-6. PubMed ID: 15643682
[TBL] [Abstract][Full Text] [Related]
10. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
[TBL] [Abstract][Full Text] [Related]
11. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study.
Pirard C; Donnez J; Loumaye E
Hum Reprod; 2006 Jul; 21(7):1894-900. PubMed ID: 16556673
[TBL] [Abstract][Full Text] [Related]
12. GnRH agonist administration after embryo transfer, in long protocol stimulated cycles, prevents ovarian hyperstimulation syndrome. A report of five cases.
Nikolettos N; Asimakopoulos B; Simopoulou M; al-Hasani S
In Vivo; 2003; 17(6):655-8. PubMed ID: 14758735
[TBL] [Abstract][Full Text] [Related]
13. [A prospective, randomized controlled study comparing the effects of gonadotropin-releasing hormone agonist long and short protocols for in vitro fertilization].
Ye H; Huang G; Pei L
Zhonghua Fu Chan Ke Za Zhi; 2001 Apr; 36(4):222-5. PubMed ID: 11783366
[TBL] [Abstract][Full Text] [Related]
14. Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation.
Malmusi S; La Marca A; Giulini S; Xella S; Tagliasacchi D; Marsella T; Volpe A
Fertil Steril; 2005 Aug; 84(2):402-6. PubMed ID: 16084881
[TBL] [Abstract][Full Text] [Related]
15. Controlled ovarian hyperstimulation in women > or = 40 years old undergoing IVF-ET: mid-luteal versus early follicular (flare-up) GnRH analog regimens.
Borini A; Trevisi MR; Bafaro MG; Cattoli M; Bianchi L; Flamigni C
Acta Eur Fertil; 1995; 26(2):59-61. PubMed ID: 9098461
[TBL] [Abstract][Full Text] [Related]
16. Accelerated endometrial maturation in the luteal phase of cycles utilizing controlled ovarian hyperstimulation: impact of gonadotropin-releasing hormone agonists versus antagonists.
Saadat P; Boostanfar R; Slater CC; Tourgeman DE; Stanczyk FZ; Paulson RJ
Fertil Steril; 2004 Jul; 82(1):167-71. PubMed ID: 15237007
[TBL] [Abstract][Full Text] [Related]
17. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates.
Acevedo B; Gomez-Palomares JL; Ricciarelli E; Hernández ER
Fertil Steril; 2006 Dec; 86(6):1682-7. PubMed ID: 17074344
[TBL] [Abstract][Full Text] [Related]
18. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.
Kolibianakis EM; Schultze-Mosgau A; Schroer A; van Steirteghem A; Devroey P; Diedrich K; Griesinger G
Hum Reprod; 2005 Oct; 20(10):2887-92. PubMed ID: 15979994
[TBL] [Abstract][Full Text] [Related]
19. Ovarian cyst formation following GnRH agonist administration in IVF cycles: incidence and impact.
Qublan HS; Amarin Z; Tahat YA; Smadi AZ; Kilani M
Hum Reprod; 2006 Mar; 21(3):640-4. PubMed ID: 16253965
[TBL] [Abstract][Full Text] [Related]
20. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
